Vaxcyte Begin Period Cash Flow from 2010 to 2024

PCVX Stock  USD 91.70  3.16  3.57%   
Vaxcyte Begin Period Cash Flow yearly trend continues to be fairly stable with very little volatility. Begin Period Cash Flow is likely to outpace its year average in 2024. Begin Period Cash Flow is the amount of cash Vaxcyte has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2019-03-31
Previous Quarter
611.5 M
Current Value
518.7 M
Quarterly Volatility
218.8 M
 
Covid
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 66.1 M, Interest Expense of 0.0 or Selling General Administrative of 63.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.16. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
  
Check out the analysis of Vaxcyte Correlation against competitors.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Latest Vaxcyte's Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of Vaxcyte over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Vaxcyte's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Slightly volatile
   Begin Period Cash Flow   
       Timeline  

Vaxcyte Begin Period Cash Flow Regression Statistics

Arithmetic Mean155,344,018
Geometric Mean834,597
Coefficient Of Variation193.81
Mean Deviation217,733,379
Median8,359
Standard Deviation301,066,672
Sample Variance90641.1T
Range877.3M
R-Value0.71
Mean Square Error48332.5T
R-Squared0.50
Significance0
Slope47,833,542
Total Sum of Squares1268976T

Vaxcyte Begin Period Cash Flow History

2024877.3 M
2023835.5 M
202269.9 M
2021386.2 M
202059 M
201966.1 M
201836.1 M

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Begin Period Cash Flow835.5 M877.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.